Fund Investments

We invest in venture capital funds, growth capital funds and late-stage private equity funds in order to access great investors at each stage of the capital and innovation cycle. We have made over 60 targeted investments in China-focused funds with top-tier managers and key sector exposure. A select sample is presented below.

 

VENTURE CAPITAL

Seed and early stage managers have played an impactful role in fueling dramatic innovation in China.

 

GROWTH CAPITAL

Growth Equity managers dominate in China capitalizing on broad economic expansion yesterday and today.

 

PRIVATE EQUITY

Larger, late stage investors offer significant opportunities as market leaders prepare for M&A and IPO transactions.

 

HEDGE FUNDS

A modest allocation to elite hedge fund managers provides enhanced liquidity and uncorrelated alpha.

Direct Investments

Sagamore seeks direct investment opportunities in non-strategic, but essential sectors in China such as agriculture, financial services and consumer products.

ASLAN PHARMACEUTICALS

ASLAN PHARMACEUTICALS

Oncology and inflammation drug discovery company based in Singapore, Taipei and Shanghai

ASLAN PHARMACEUTICALS
Sagamore was a founding investor in ASLAN in 2010, leading the Series A investment alongside its affiliate fund BV Healthcare. The Series B financing was led by Shanghai-based Cenova Ventures with participation from Morningside Group and Taiwan-based XinChen Ventures.
GRASSLAND</br> FINANCE

GRASSLAND
FINANCE

Hong Kong-based financial services holding company serving the micro, small and medium-sized enterprises (MSMEs) in China

GRASSLAND</br> FINANCE
From an initial investment in 2013 in the profitable operations in Chifeng, Inner Mongolia started by Accion International in 2009, Grassland now operates in Wanzhou, Chongqing as well and has pending licenses in Hunan and Pudong. Sagamore is the largest shareholder and is targeting an IPO in 2019.
LUFAX

LUFAX

Leading online peer-to-peer (P2P) and non standard asset (NSA) trading platform

LUFAX
Founded in Sep 2011 as a subsidiary of the PingAn Group, Lufax is presently among the very largest P2P platforms in China. Sagamore invested in Jan 2015 and expects an IPO in 2017.
MONTAGE TECHNOLOGY

MONTAGE TECHNOLOGY

Leading Fabless semiconductor company based in Shanghai

MONTAGE TECHNOLOGY
Late-stage pre-IPO purchase of founder shares in Mar 2013. Company went public in Sep 2013 and Sagamore sold shares in four tranches over Jan to May 2014 for net return of 1.7x and an 85% IRR.
XIAOMI

XIAOMI

Largest smartphone distributer in China that designs, develops and sells phones, mobile apps and consumer electronics

XIAOMI
Sagamore invested in the firm's Series F alongside DST, GIC, Hopu and Yunfeng. Targeting an IPO within five years.
CITIC </BR> PHARMACEUTICALS

CITIC
PHARMACEUTICALS

Pharmaceutical manufacturing and distribution company in Shanghai

CITIC </BR> PHARMACEUTICALS
Sold to Shanghai Pharma for 8.0x multiple and an IRR of 69%. Invested in Apr 2007 and harvested in Mar 2011.

History

Sagamore's founders have worked together since 2002 and have invested in over 100 funds and companies in Asia and the US. Sagamore's first investments focused on biotechnology and expanded to fund and direct investments in China with Sagamore China Partners I (SCP I) in 2006. The team raised subsequent funds SCP II (2010), SCP III (2013) and SCP IV (2016). In total, Sagamore has over $400m in assets under management for investing in opportunities in China.

2002
Firm Established
2006
Sagamore China Partners I
2010
Sagamore China Partners II
2013
Sagamore China Partners III
2016
Sagamore China Partners IV

Team

Led by seasoned entrepreneurs, founders Peter Brooks and Rodrigo Yang, the firm's five professionals are based in Beijing (sourcing and diligence) and Hong Kong (investment analytics).

Rodrigo Yang
Peter Moody Brooks
Jing Wang
Edward Cumberlege
Nick Wang

Contact

Sagamore has offices in Beijing, Hong Kong and Shanghai. We are always looking for exciting business opportunities and new talent to join our team. Please contact us for more information.

 

Beijing

Room 901, Block F, Phoenix Place, Tower 21, No. A5 Shuguangxili, Chaoyang District, Beijing, 100028

 

Hong Kong

Level 6, Citibank Tower,
Citibank Plaza, 3 Garden Road,
Central, Hong Kong


 

Shanghai

Room 908, 108 Yu Yuan Road, Jing'an District,
Shanghai, 200040